AIM ImmunoTech Files 8-K for Material Agreement

Ticker: AIM · Form: 8-K · Filed: Apr 4, 2025 · CIK: 946644

Sentiment: neutral

Topics: material-agreement, filing, biotech

TL;DR

AIM ImmunoTech signed a material deal, check the 8-K for details.

AI Summary

AIM ImmunoTech Inc. filed an 8-K on April 4, 2025, reporting a material definitive agreement and financial statements. The filing pertains to the period ending April 1, 2025. The company is based in Ocala, Florida, and operates in the Biological Products sector.

Why It Matters

This 8-K filing indicates AIM ImmunoTech has entered into a significant agreement, which could impact its business operations and financial standing.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's future performance.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement filed by AIM ImmunoTech?

The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in this excerpt.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on April 1, 2025.

What is AIM ImmunoTech Inc.'s principal executive office address?

The principal executive offices are located at 2117 SW Highway 484, Ocala FL 34473.

What was AIM ImmunoTech Inc. formerly known as?

The company was formerly known as HEMISPHERX BIOPHARMA INC.

What is the SIC code for AIM ImmunoTech Inc.?

The Standard Industrial Classification (SIC) code is 2836, for Biological Products (no diagnostic substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 4, 2025 regarding AIM ImmunoTech Inc. (AIM).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing